WHO Recommends Two Monoclonal Antibody Treatments for Ebola

The World Health Organization (WHO) has recommended two monoclonal antibody treatments for Ebola patients — Regeneron’s Inmazeb (REGN-EB3) and Ridgeback Biotherapeutics’ Ebanga (mAb114, ansuvimab).

The agency is recommending the drugs for all patients confirmed positive for Ebola virus infection including older people, pregnant and breastfeeding women and children and newborns born to mothers with confirmed Ebola within the first seven days after birth.

The agency said that the two drugs had demonstrated clear benefits, but that there is a need for further evaluation.